Trial Profile
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Afamitresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Adenocarcinoma; Bladder cancer; Gastric cancer; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Myxoid liposarcoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Synovial sarcoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Adaptimmune
- 19 Jan 2024 Planned End Date changed from 1 Sep 2035 to 1 Sep 2032.
- 19 Apr 2023 Results from NCT03132922 and NCT04044768, exploring the cooperation between afamicel induced innate and adaptive immune responses , presented at the 114th Annual Meeting of the American Association for Cancer Research
- 01 Jan 2023 Results(n=38) assessing the safety anf efficacy of T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients published in the Nature Medicine